新闻稿 Better prevention of transmission and lesion development of genital herpes predicted for AiCuris drug AIC316
预防生殖器疱疹的传播和病变发展更好地预测药物AIC316 AiCuris Data showing stronger reduction of clinically relevant viral shedding in comparison with nucleosides to be presented at upcoming conferences
数据显示出较强的临床相关的病毒脱落减少比较，将在即将召开的会议提出的与核苷 Wuppertal, 16th April 2012 - AiCuris announced today that in depth analysis of data from the AIC316 Phase 2 trial in patients with genital herpes will be disclosed at several international meetings.
2012年4月16日乌珀塔尔 - AiCuris今天宣布，从AIC316二期生殖器疱疹患者的试验数据进行深入分析，将在多个国际会议上披露。
This information adds to the very favourable efficacy data meeting the primary endpoint of the trial which have already been announced.
此信息添加到了十分有利的疗效数据，满足对已公布的试验的主要终点。
It further highlights the superiority of AIC316 in the treatment of genital herpes.
它进一步凸显了AIC316在治疗生殖器疱疹的优越性。
The reduction of shedding of genital herpes simplex virus (HSV) by AIC316 in the recent Phase 2 trial will be compared with data from clinical trials with nucleoside analogues.
减少脱落AIC316的生殖器单纯疱疹病毒（HSV）在最近的第2阶段试验将与核苷类似物的临床试验数据进行比较。
AIC316, a HSV inhibitor with a novel mode of action and much improved half-life, shows superior reduction of shedding events associated with high viral load, which is regarded as clinically relevant for HSV lesion development and transmission.
AIC316，与行动的新模式，单纯疱疹病毒抑制剂，半衰期大大改善，显示了优越的减少脱落与病毒载量高，这是临床HSV病变的发展和传输有关的事件。
AiCuris project leader Dr. Alexander Birkmann will present the data at the International Conference on Antiviral Research (ICAR) meeting in Sapporo, Japan, on 19th April 2012.
AiCuris项目领导人的亚历山大Birkmann博士将出席在日本札幌国际抗病毒研究会议（ICAR）2012年4月19日会议的数据。
Furthermore, Professor Helga Rübsamen-Schaeff, CEO of AiCuris, will give an invited talk on AIC316 discussing this topic at the International Herpesvirus Workshop in Calgary, Canada, 4th-9th August 2012.
此外，海尔格Rübsamen，Schaeff AiCuris的首席执行官，教授会讨论这个主题，在国际疱疹研讨会在加拿大卡尔加里，2012年8月第4 9 AIC316邀请谈话。
"Encouraged by this data the planning and preparation of the Phase 3 program is now underway with high priority" comments Dr. Marie Paule Richard, CMO of AiCuris.
评论的AiCuris奇美玛丽Paule理查德博士，“这第3阶段计划的规划和准备，现在正在进行中具有高优先级的数据鼓舞”。
For additional information on AiCuris please visit www.aicuris.com or contact
为对AiCuris其他信息，请访问
www.aicuris.com或联系
AiCuris GmbH & Co. KG AiCuris GMBH＆CO。KG
Sandra Wildhagen 桑德拉Wildhagen
| Phone 电话
Fax 传真
| +49 202 317 63 1176 +49 202 317 63 1176
+49 202 317 63 1177 +49 202 317 63 1177
|
Friedrich-Ebert-Str. 弗里德里希·艾伯特-STR。 475 475
Building 302 建设302
42117 Wuppertal 42117伍珀塔尔
| Email 电子邮件
Internet 因特网
| press@aicuris.com press@aicuris.com
www.aicuris.com www.aicuris.com
|
***
***
About AIC316
关于AIC316 AIC316 is an innovative, highly active and specific inhibitor of herpes simplex virus (HSV) addressing a novel target (the viral helicase-primase complex).
AIC316是一个创新的，非常积极和具体的抑制单纯疱疹病毒（HSV）的寻址一个新的目标（病毒解旋酶，引物酶复杂）。
It also stems from a novel chemical class (thiazolylamides).
它还源于一种新的化学类（thiazolylamides）。
AIC316 is active against both labial and genital herpes virus strains.
AIC316是积极对两唇与生殖器疱疹病毒株。
Based on this new mode of action - and in contrast to nucleoside analogues - AIC316 does not require activation by viral thymidine kinase and therefore, is active - and protective - in uninfected cells.
基于这一行动的新模式 - 对比核苷类似物 - AIC316不需要病毒胸苷激酶的活化，因此，活跃 - 在未受感染的细胞 - 保护。
Similarly, due to its different mode of action, AIC316 also retains full activity against viruses that are resistant to marketed drugs.
同样，由于其不同的行动模式，AIC316还保留了对销售的药品有抗药性的病毒活动。
The favorably long plasma half-life of AIC316 on the one hand protects cells for extended periods of time against infection by the virus, on the other hand it is offers very convenient dosing regimens for patients (expected: one pill per episode for treatment of a herpes episode, once weekly treatment for suppression of genital herpes).
有利长期血浆的AIC316半衰期一方面保护细胞对病毒感染时间为长时间，另一方面是，提供了非常方便的给药方案：患者（预计为每一个情节丸治疗疱疹发作，抑制生殖器疱疹每周一次治疗）。
***
***
